Akero Therapeutics (AKRO) Environmental, Social & Governance (ESG) Data

Employees

Data from SEC filings

Employee count

ESG framework mentions

In last year of SEC filings

Sustainability Accounting Standards Board (SASB)

No mentions

Global Reporting Initiative (GRI)

No mentions

Task Force on Climate-related Financial Disclosures (TCFD)

No mentions

UN Sustainable Development Goals (SDGs)

No mentions

ESG term mentions

In last year of SEC filings

Climate Environment Environmental Environmental Protection Hazard Materials Mineral Nature Offset Package Packaging Pandemic Toxic Waste Access African American Asian Benefits Black California Consumer Privacy Act Community Culture Customer Cyber Cyber Security Cybersecurity Data Privacy Data Security Death Demographic Demographics Disability Diversity Drug Pricing Employee Engagement Ethnicity Gender General Data Protection Regulation Health and Safety Health Care Healthcare Hire Hiring Hispanic Human Capital Human Resources Injured Injuries Injury Latinx LGBTQ Minority Perquisites Privacy Product Quality Recall Recruit Recruitment Reimbursement Retention Retirement Safety Satisfaction Skilled Skills Social Stakeholder Supplier Supply Chain Talent Training Union Volunteer Women Workers Working Condition Anti-corruption Assessment Assurance Attorneys General Audit Bonus Bribery Classified Commitment Conflict of Interest Corporate Governance Department of Ethics Executive Compensation Expert Fraud Goals Governance Hedging Incentive Incentivize Independence Independent Independent Chair Innovation Innovative Investigation Lawsuit Leadership Litigation Long-term Majority Mission Oversee Oversight Perquisite Pledging Proxy Access Proxy Contest Purpose Quality Standard R&D Recoup Reputation Reputational Reputational Risk Research and Development Responsibility Responsible Special Meeting Strategy Sustainable Targets Tax Tenure Transparency

Shareholder alignment

Proxy contests and exempt solicitations in last 3 years

No recent proxy contest or exempt solicitation filings from shareholders.

Vote support at last AGM

Akero Therapeutics, Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”) on June 1, 2021. As of April 5, 2021, the record date for the Annual Meeting, there were 34,820,319 outstanding shares of the Company’s common stock. The Company’s stockholders voted on the following matters, which are described in detail in the Company’s Definitive Proxy Statement filed with the U.S. Securities and Exchange Commission (“SEC”) on April 27, 2021: (i) to elect three directors, Seth L. Harrison, M.D., Graham Walmsley, M.D., Ph.D., and Yuan Xu, Ph.D., as Class II directors of the Company to each serve for a three-year term expiring at the Company’s annual meeting of stockholders in 2024 and until their successors have been duly elected and qualified, subject to their earlier death, resignation or removal (“Proposal 1”) and (ii) to ratify the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2021 (“Proposal 2”).

The Company’s stockholders approved the Class II director nominees recommended for election in Proposal 1 at the Annual Meeting. The Company’s stockholders voted for Class II directors as follows:

Class II Director Nominee
Seth L. Harrison, M.D.	21,800,912	4,780,457	5,298,544
Graham Walmsley, M.D., Ph.D.	21,775,483	4,805,886	5,298,544
Yuan Xu, Ph.D.	26,548,435	32,934	5,298,544

The Company’s stockholders approved to ratify the appointment of Deloitte & Touche LLP in Proposal 2. The votes cast at the Annual Meeting were as follows:

For				Against				Abstain
	31,788,019				12,437				79,457

No other matters were submitted to or voted on by the Company’s stockholders at the Annual Meeting.

* * *